OncoMatch/Clinical Trials/NCT02203903
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Is NCT02203903 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Tumor associated antigen lymphocytes (TAA-T) for relapsed/refractory hematopoietic malignancies, acute myeloid leukemia and mds.
Treatment: Tumor associated antigen lymphocytes (TAA-T) — This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
have received or will receive an allo-HSCT and have not had hematologic relapse of disease
Cannot have received: second allogeneic hematopoietic stem cell transplant
Patients who have or will be receiving 2nd allogeneic HSCT
Cannot have received: T cell immunosuppressive monoclonal antibody (ATG, Campath)
Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies within 28 days prior to TAA-T infusion
Cannot have received: investigational therapy
No investigational therapies (under IND, not extensively studied in the current clinical context) within 28 days prior to TAA-T infusion
Lab requirements
Blood counts
Absolute neutrophil count > 250/µL (may be supported with GCSF)
Kidney function
Serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher)
Liver function
Bilirubin < 2.5 mg/dL, AST/ALT <5x upper limit of normal
Cardiac function
LVEF > 50% or LVSF > 27% (performed within the last 6 months) if history of TBI >500 cGy for arm A and B
Bilirubin < 2.5 mg/dL, AST/ALT <5x upper limit of normal, Serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher). Pulse oximetry of > 90% on room air. Absolute neutrophil count > 250/ µL (may be supported with Granulocyte colony-stimulating factor (GCSF)). LVEF > 50% or LVSF > 27% (performed within the last 6 months) if history of TBI >500 cGy for arm A and B.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Childrens National Medical Center · Washington D.C., District of Columbia
- Tania Jain, MD · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify